Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    AROENaC1001
Previous Study | Return to List | Next Study

Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04375514
Recruitment Status : Terminated (Business decision)
First Posted : May 5, 2020
Last Update Posted : February 24, 2022
Sponsor:
Information provided by (Responsible Party):
Arrowhead Pharmaceuticals

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) of single doses of ARO-ENaC in healthy adult volunteers; and to evaluate the safety, tolerability, PK and efficacy of multiple doses of ARO-ENaC in patients with pulmonary cystic fibrosis.

Condition or disease Intervention/treatment Phase
Cystic Fibrosis, Pulmonary Drug: ARO-ENaC Drug: Placebo Phase 1 Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 43 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-ENaC in Normal Healthy Volunteers and Safety, Tolerability and Efficacy in Patients With Cystic Fibrosis
Actual Study Start Date : August 10, 2020
Actual Primary Completion Date : September 3, 2021
Actual Study Completion Date : September 3, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: ARO-ENaC
ARO-ENaC Inhalation
 Drug: ARO-ENaC
single or multiple doses of ARO-ENaC by inhalation of nebulized solution
Placebo Comparator: Placebo
Sterile normal saline (0.9% NaCl)
 Drug: Placebo
calculated volume to match active treatment by inhalation of nebulized solution


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of Participants with Adverse Events (AEs) Possibly or Probably Related to Treatment [ Time Frame: single dose phase: Up to 29 (+/- 2) days; multiple dose phase: Up to 113 (+/- 5 days) post-dose for patients with CF ]

Secondary Outcome Measures :
  1. Change from Baseline in Serum Electrolytes: Potassium, Sodium, Bicarbonate and Chloride (all in mmol/L) [ Time Frame: Baseline, single dose phase: Up to 29 (+/- 2) days; multiple dose phase: Up to 113 (+/- 5 days) post-dose for patients with CF ]
  2. Change from Baseline in Forced Expiratory Volume (FEV1) in Normal Healthy Volunteers [ Time Frame: Baseline, Up through Day 29 after a single dose ]
  3. PK of ARO-ENaC: Maximum observed Plasma Concentration (Cmax) [ Time Frame: single dose phase: Up through Day 5; multiple dose phase: Up through Day 30 (+/- 2 days) ]
  4. PK of ARO-ENaC: Time to Maximum Plasma Concentration (Tmax) [ Time Frame: single dose phase: Up through Day 5; multiple dose phase: Up through Day 30 (+/- 2 days) ]
  5. PK of ARO-ENaC: Terminal Elilmination Half-Life (t1/2) [ Time Frame: single dose phase: Up through Day 5; multiple dose phase: Up through Day 30 (+/- 2 days) ]
  6. PK of ARO-ENaC: Area Under the Plasma Concentration Versus Time Curve From Zero to 24 Hours (AUC0-24) [ Time Frame: single dose phase: Up through Day 5; multiple dose phase: Up through Day 30 (+/- 2 days) ]
  7. PK of ARO-ENaC: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUCinf) [ Time Frame: single dose phase: Up through Day 5; multiple dose phase: Up through Day 30 (+/- 2 days) ]
  8. PK of ARO-ENaC: Area Under the Plasma Concentration Versus Time Curve From Zero to the Last Quantifiable Plasma Concentration (AUClast) [ Time Frame: single dose phase: Up through Day 5; multiple dose phase: Up through Day 30 (+/- 2 days) ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding, and must be willing to use contraception
  • Willing to provide written informed consent and to comply with study requirements
  • Normal electrocardiogram (ECG) at Screening
  • Non-smoking
  • Normal pulmonary function tests at Screening (NHVs only)
  • No abnormal finding of clinical relevance at Screening other than CF for CF patients
  • Confirmed diagnosis of CF based on source verifiable medical record (CF patients only)
  • All other treatments for CF have been stable for at least 2 months and patient is willing to continue this treatment regimen without change for duration of study (CF patients only)

Exclusion Criteria:

  • Acute lower respiratory infection within 30 days of Screening (NHVs only)
  • History of asthma (specifically, those subjects at risk of bronchial hyperactivity), anaphylaxis or airway hyper-reactivity
  • Clinically significant history of hyperkalemia or presence of hyperkalemia at Screening
  • Clinically significant health concerns (other than CF in CF patients)
  • Human Immunodeficiency virus (HIV) infection, seropositive for Hepatitis B Virus (HBV), seropositive for Hepatitis C Virus (HCV)
  • Uncontrolled hypertension
  • Excessive use of alcohol within one month prior to Screening
  • Use of illicit drugs within 1 year prior to Screening
  • Use of an investigational agent or device within 30 days prior to dosing or current participation in an investigational study
  • CF exacerbation within 30 days of Dosing (CF patients)
  • History of solid organ transplant (CF patients)
  • Diagnosis of hepatic cirrhosis (CF patients)

Note: additional inclusion/exclusion criteria may apply per protocol

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04375514


Locations
Layout table for location information
Australia, Queensland
Research Site
Chermside, Queensland, Australia, 4032
Research Site
South Brisbane, Queensland, Australia, 4101
Australia, Western Australia
Research Site
Nedlands, Western Australia, Australia, 6009
Australia
Research Site
Hamilton, Australia, 3204
New Zealand
Research Site
Grafton, Auckland, New Zealand, 1010
Research Site
Christchurch, New Zealand, 8140
Research Site
Dunedin, New Zealand, 9054
Sponsors and Collaborators
Arrowhead Pharmaceuticals
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Arrowhead Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04375514    
Other Study ID Numbers: AROENaC1001
First Posted: May 5, 2020    Key Record Dates
Last Update Posted: February 24, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Pulmonary Fibrosis
Fibrosis
Pathologic Processes
Pancreatic Diseases
 Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases